If you have questions, please call us for more information about clinical trials or use our online form.

Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.  

Displaying 71 - 80 of 290

Combination Post-Transplant Consolidation Therapy with Isatuximab, Lenalidomide, Dexamethasone (IsaRD) in Multiple Myeloma Patients with Persistent Marrow Minimal Residual Disease (Elimination of MRD After Transplant; E-MAT)

The purpose of this study is to test the safety and effectiveness of the new study drug combination of Isatuximab, Lenalidomide, and Dexamethasone for the treatment of multiple myeloma in patients with Persistent Marrow Minimal Residual Disease.
Protocol No